Walder Wyss AG advised BUCHI on the transaction. BUCHI Labortechnik AG announced the acquisition of the NeoSpectra platform from Si-Ware Systems, including Si-Ware Systems’ handheld NIR...
BUCHI Labortechnik AG’s Acquisition Of NeoSpectra Platform From Si-Ware Systems
Helvetia AG’s Merger With Baloise AG
Lenz & Staehelin and Freshfields advised Baloise on the deal. Walder Wyss and Clifford Chance advised Helvetia. Baloise Holding Ltd and Helvetia Holding Ltd have announced...
Infineon Technologies’ Acquisition of 3db Access
Walder Wyss advised Infineon on the transaction. Infineon Technologies, a global semiconductor leader in power systems and IoT, has acquired the Zurich-based startup 3db Access, a...
Merck’s Win Commercial Contract Litigation in Canton Of Zurich Court
Walder Wyss represents Merck in the Swiss proceedings. The Federal Supreme Court confirms far-reaching injunctions granted in favor of the German science and technology company Merck...
ITS Kanal Services AG’s Acquisition of Restclean AG
Walder Wyss advised ITS Kanal Services Ltd on the acquisition. ITS Kanal Services AG acquired Restclean AG. Restclean AG is a specialist in the field of...
Alentis Therapeutics’ $105 Million Series C Funding Round
Walder Wyss advises Alentis Therapeutics on the financing. Alentis Therapeutics has announced $105 million in Series C financing. The funding round was led by Jeito Capital...
Intel 471’s Acquisition of SpiderFoot
Walder Wyss and TGS Baltics advised the selling founder as lead counsel. Magnusson advised the acquirer Intel 471 in-cooperation with Loyens & Loeff (Switzerland), Reed Smith...
Cembra Money Bank’s CHF 60 Million Acquisition of Byjuno and Intrum Finance Services
Pestalozzi advised Intrum on the deal. Walder Wyss has advised Cembra on the transaction. Byjuno was founded by Intrum AG in 2014 and is one of...
Vector BioPharma’s USD 30 Million Series A Funding Round
Walder Wyss advised Versant Ventures on the deal. Versant Ventures announced the debut of Vector BioPharma, a biopharmaceutical company developing a precision gene delivery platform that...
Alentis Therapeutics’ $67 Million Series B Financing Round
Walder Wyss advised Alentis Therapeutics AG on the deal. Alentis Therapeutics AG announced a USD 67m series B financing round. Morningside Venture Investments led the financing, joined...